GlassScriptPhysician profile
Nativel J Collins
NPI 1437162690
$72,995.00
in general payments reported to CMS, 2019-2025
29 companies · $935 in 2025
The $935 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37K · 2022: $29K · 2023: $4,263 · 2024: $866 · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,362 · Food and Beverage: $2,669 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,362.25 |
| Food and Beverage | $2,669.00 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $58,130.36 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $9,206.90 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,078.67 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Medtronic, INC. | $787.21 | 2021-2025 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $420.26 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $406.71 | 2021-2025 | Jardiance, Synjardy |
| Amgen INC. | $331.62 | 2021-2025 | Repatha, Otezla, Evenity |
| Xeris Pharmaceuticals, INC. | $309.08 | 2021-2024 | Gvoke Hypopen |
| Dexcom, INC. | $258.71 | 2021-2023 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $239.26 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $236.45 | 2021-2023 | |
| Esperion Therapeutics, INC. | $223.41 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $221.18 | 2021-2023 | Steglatro |
| Insulet Corporation | $219.94 | 2021-2025 | Omnipod |
| Abbott Laboratories | $170.83 | 2021-2023 | Freestyle Libre |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $170.82 | 2022 | |
| Sequel Med Tech, LLC | $134.62 | 2025 | Twiist |
| Corcept Therapeutics | $97.08 | 2025 | Korlym |
| Lifescan, INC. | $62.58 | 2021-2022 | |
| Rochester Medical Corporation | $48.59 | 2021 | |
| Pfizer INC. | $45.73 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $34.39 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $32.80 | 2021-2022 | |
| Grt US Holding, INC. | $31.11 | 2022 | |
| Cequr Corporation | $21.04 | 2025 | Cequr Simplicity |
| Vifor Pharma, INC. | $20.27 | 2021 | |
| Glaxosmithkline, LLC. | $20.01 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $18.26 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.11 | 2024 | Xifaxan, Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nativel Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.